HEPATITIS B VACCINE

Abstract: A polypeptide vaccine is disclosed with the amino acide sequence of Asp-Pro-Arg-Val-Arg-Gly-Leu-Try-Phe-Pro-Ala-­ Gly-Gly-Ser-Ser-Ser-Gly-Thr-Val that bears the receptor for polymerized human serum albumin capable of raising anti­ bodies to inhibit the access and entry of hepatitis B virus (HBV) to hepatocytes. The polypeptide vaccine is also shown in which the 9th amino acid residue (Phe) is replaced by leucine.

Description: The present invention relates to hepatitis B vaccine. On a world-wide scale, infection with hepatitis B virus (HBV) represents one of the major problems in public health care. There are an estimated 200 million persons who are carriers of HBV. These carriers are mostly asymptomatic, that is, they exhibit little or no symptoms of the disease. However, some of these persons develop a spectrum of hepatic diseases ranging from acute hepatitis to hepatocellular carcinoma. Furthermore, they constitute a reservoir of HBV in the community from which the virus is transmitted vertically (perinatal infection from mother to child) and horizontally (through intimate body contacts). A viral infection of a healthy organism occurs when a virus attaches itself to a receptor site on the cell, enters the cell and then takes over the cell's machinery to make copies of the virus. Eventually the cell lyses or bursts. The hosts immune system produces antibodies which function by attaching themselves to the virus in the bloodstream and blocking its ability to attach to the host cells. The technology of vaccines and vaccination must surely rank as one of the most important developments of all times. Some diseases have been virtually eliminated thereby while others have been brought under control with a considerable saving in human lives. In general, the process of vaccination is carried out by injecting a virus into a living host in order to make the host produce antibodies capable of neutralizing or inhibiting the virus. The virus that is used for this injection process is normally a killed virus or an attenuated virus; that is, a virus that has been reduced in virulence by passage through a host other than its normal one. However successful these procedures have been, they are not without problems. For example, an attenuated virus can mutate and increase in virulence; also the long term effect of such latent viruses is not fully known. Still further, killed viruses may not be completely inactivated and may cause infections. Other problems also arise because of the fact that the virus must be grown in order to produce killed virus or attenuated virus vaccines. Therefore, there is a potential for accidental venting of such organisms to the environment. Thus, there is the need for special handling and storage facilities for such substances, which need may become difficult to fulfil in some underdeveloped countries. As a result of the problems that have been encountered over the years in producing, storing and using vaccines produced from viruses, efforts have been made to produce synthetic vaccines. These synthetic vaccines are not based on killed viruses or attenuated viruses but consist of short protein chains called "peptides". The concept of synthetic vaccines is to synthesize in the laboratory a short protein chain that mimics a small region of the outer coat of the virus and which is capable of stimulating the production of antibodies in the host that will neutralize the virus and prevent the virus from infecting a cell. Preferably the region mimicked is involved with binding of the virus to the host cell. The synthetic peptide, like the virus itself, elicits the production of antibodies by the host which antibodies will then function to bind to the surface of the virus corresponding to the peptide and neutralize the virus by blocking the sites whereby the virus would be able to attach to healty cells to initiate the infection process. HBV has been shown by research workers to be a unique DNA virus. DNA viruses that closely mimic HBV are found in species other than humans, such as woodchuck, duck and ground squirrel, and constitutes a family that is called hepadna virus. HBV has a diameter of 42 nm, and is made up of an internal core representing a viral nucleocapsid and an outer coat. These constituents of HBV are different antigenically. The outer coat is made of viral protein with the antigenicity of hepatitis B surface antigen (HBsAg), whereas the inner core or core particles contain nucleoprotein with a molecular size of 19,000 daltons (P19), in addition to the viral DNA and its polymerase. P19 bears the antigenicity of both hepatitis B core antigen (HBcAg) and hepatitis B e antigen (HBeAg). HBeAg is expressed along the N-terminus, while HBcAg is expressed at the part exposed to the surface when P19 molecules are assembled to make the core particle. In hepatocytes infected with HBV, the viral coat, HBsAg, is produced far in excess of core particles, so that HBsAg itself appears in the circulation in spherical and tubular forms, both with a diameter of 22 nm. The fact that the viral nucleocapsid is covered with HBsAg can be used advantageously for the prevention of HBV infection by immunological means. Antibody to HBsAg (anti-HBs) may be given to susceptible persons as passive immunoprophylaxis, and 22-nm HBsAg particles may be used as a vaccine in active immunoprophylaxis. It is widely known that HBV has a narrow host range and narrow organ specificity. Tests have established that only hepatocytes from humans and chimpanzees are vulnerable to HBV infection. Such organ tropism would be responsible for the site on HBV that gains access to human and chimpanzee hepatocytes with a specificity of a "lock and key". Factors that react with polymerized human serum albumin (poly-HSA)have been identified in serums from patients with various hepatic disorders and these factors are ascribed to antibodies against denatured albumin molecules. For reasons not fully understood, these factors, detected by the agglutination of sheep red blood cells (SRBC) coated with poly-HSA, were found more often in serums which were positive for HBeAg. HBV infection can be divided into the HBeAg-phase when HBeAg can be detected in the serum along with Dane particles (presently accepted as HBV) and the anti-HBe phase when antibody to HBeAg is detected but Dane particles and free HBeAg are detected only rarely. It has been found that not every HBsAg-positive serum agglutinates SRBC coated with poly-HSA; of those HBsAg-positive serums which do, those containing HBeAg show much higher agglutination titres than those containing anti-HBe. Unexpectedly, it has been found that the agglutination of poly-HSA-coated cells by HBsAg-positive serums is not due to antibodies as was initially suspected. Applicants have found that Dane particles, as well as HBsAg particles, are directly involved in the reaction with poly-HSA-coated cells. Utilizing immune electron microscopy, Dane particles and 22-nm HBsAg particles derived from HBeAg-positive plasma were shown to aggregate in the presence of poly-HSA, in contrast to 22-nm HBsAg particles obtained from anti-HBe-positive plasma that did not show such aggregation. On the basis of these observations, a receptor for poly-HSA has been described by applicants on the surface of Dane particles and 22-nm HBsAg particles that co-occur with HBeAg, but not on 22-nm particles that co-exist with anti-HBe. The poly-HSA receptor of HBAg was found to be species-specific, because it will react with polymerized albumins from human and chimpanzee, but will not react with polymerized albumins from animals without a susceptibility to HBV, such as mouse, rabbit and horse. These observations by the applicants strongly suggested that the poly-HSA receptor on HBV would be involved in the species specificity of the virus in infection of hepatocytes. Albumin is produced by hepatocytes and represents the most abundant protein in the circulatory system. A constant level of albumin is maintained in the bloodstream. Aged albumin molecules aggregate spontaneously and are taken up by hepatocytes that have the receptor for aggregated (polymerized) albumin. Human and animal hepatocytes are known to have the receptor for polymerized albumin, but not for a monomeric albumin of their own and other species. Aggregated albumin molecules, forming constantly in the circulation, adhere to hepatocytes by means of the hepatocytes receptor for poly-HSA. When Dane particles are introduced into the circulation, they would be able to gain entry to hepatocytes by way of the poly-HSA that would act as a connector. As such, the affinity of HBV to hepatocytes would be not a direct one. It would be ascribable to the mutual affinity to a third party (aggregated albumin) which can bridge them and effect their coming in contact. In a rate zonal ultracentrifugation in CsCl, HBsAg particles derived from HBeAg-positive plasma, and bearing the receptor for poly-HSA, banded at a higher density (1.213 g/cm³) than those obtained from anti-HBe-positive plasma and without the receptor (1.203 g/cm³. When the heavy HBsAg particles were treated with pronase, their density was lowered to approach to that of light HBsAg particles and they lost the receptor reactivity. These observations indicated that the HBsAg particles that co-occur with the receptor may be associated with additional molecules that are responsible for the receptor. When HBsAg particles derived from HBeAg-positive plasma were broken into their constituent polypeptides by a treatment with detergent and a reducing agent, polypeptides with estimated molecular size of 31,000 and 35,000 daltons were found, in additon to the major polypeptide of HBsAg composed of 226 amino acid residues (P22) and its glucosylated form, P27. HBsAg particles from HBeAg-positive plasma were much richer in content of P31 and P35 than those derived from anti-HBe-positive plasma (11.4 ± 0.3% vs. 1.6 ± 0.4% on the basis of their percentage in the densitometer tracing, P < 0.001). P35 had the same amino acid composition as that of P31, and the difference in their molecular size was attributed to a carbohydrate moiety attached to P35. Thus P35 is the glucosylated form of P31 as P27 is the glucosylated form of P22. Both P31 and P35 exhibited binding activity to poly-HSA with a binding curve quite similar to that of HBsAg particles with the receptor. On the basis of these findings, P31 (and P35) was considered to be responsible for the poly-HSA receptor on the HBsAg particles derived from HBeAg-positive plasma. The fact that P31 was capable of binding with polymerized albumins from humans and chimpanzees, but not to those from animals without susceptibility to HBV, was additional evidence in support of such view. Using polypeptide composition and terminal amino acid sequences as a guide, the equivalent amino acid sequence of P31 was searched for on the nucleotide sequence of HBV-DNA of the same subtype ( adr ) as the HBsAg particles that served a source of P31. P31 had the C-terminal amino acid sequence of -Val-Tyr-Ile, identical to that of P22. The N-terminal residue of P22 is methionine. Adjacent to the N-terminal sequence of the P22 gene, there is a region called "pre-S". In the encoded Pre-S region sequence, the 55th amino acid residue from the N-terminal of P22 was reported to be methionine, irrespective of subtypes. The putative amino acid sequence of 281 residues (226 for P22 plus the adjacent 55 in the Pre-S region creating a molecular size of 31,142 daltons) was calculated to have the amino acid composition very similar to that determined for P31. Since P22 did not exhibit the receptor reactivity, the amino acid sequence of 55 residues on P31 and P35 that is encoded by the pre-S region of HBV-DNA was reasonably suspected to bear the receptor. Because there were no methionine residues between the N-terminal of P22 and 55th amino acid counted into the pre-S region from it, a method capable of splitting polypeptide at methionine residues, such as use of CNBr was expected to liberate the pre-S amino acid sequence from P31 and P35. When P31 was treated with CNBr and then subjected to high-performance liquid chromatography, a peptide with estimated molecular size of 8,000 daltons (P8) was obtained. P8, associated with a carbohydrate moiety, had an amino acid composition almost identical to that of the 55-amino acid polypeptide in the pre-S sequence. Furthermore, P8 was found to be capable of binding with polymerized albumins only from humans and chimpanzees, thereby indicating that it bears the receptor for poly-HSA. Along the amino acid sequence encoded by the pre-S region of HBV-DNA's of 3 different subtypes, a region of high local hydrophilicity was identified by the applicants. A peptide of 19 amino acid residues containing the region with the high local hydrophilicity, which was commonly expressed by HBV-DNA's of subtypes adr and ayw , was chemically synthesized (the sequence encoded by HBV-DNA of subtype adw was different only in that it had leucine as the 9th amino acid residue in place of phenylalanine encoded by the HBV-DNA's of the other subtypes). The peptide was designated Asp-peptide by the applicants and when conjugated with ovalbumin and emulsified in Freund's complete adjuvant, could raise antibodies in guinea pigs that bound with the receptor on HBsAg. Applicants' findings therefore indicated that the Asp-peptide, as well as P31 and P35 bearing the receptor for poly-HSA, may be used as hepatitis B vaccines. They are different in principle from the conventional vaccines, a form of HBsAg particles, in that they can raise antibodies that specifically block the site on HBV (the poly-HSA receptor) that is required for the HBV to gain access and entry to hepatocytes. Before the Applicants, Neurath et al (Science vol. 244, 27.04.84, pp. 392-395) have located and chemically synthetized a pre-S-gene coded immuno dominant epitope of HBV. In particular, the highly hydrophilic region corresponding to residues 120 to 145 has been selected for synthesis. The present peptide differs from the known one in that it corresponds to the residues 133-151 and therefore contains also a non-hydrophilic position. The availability of Asp-peptide is limited only by the constraints of its chemical synthesis. Moreover, it may also raise protective antibodies in non-responders to the conventional HBsAg vaccine who are estimated as 5% of all those vaccinated. HBV is transmitted by blood, and its products, contaminated with the virus. HBV was discovered by Dane and his co-workers in 1970 in blood containing Australia antigen (hepatitis B surface antigen, HBsAg), and represents a spherical DNA virus with an internal core. Plasma of humans infected with HBV, when ultracentrifuged and observed in an electron microscope, reveals large spherical particles with a diameter of 42 nm (Dane particles) and small spherical and tubular particles with a diameter of 22 nm. The Dane particle has an internal core with a diameter of 27 nm (core particle) that is covered with an outer shell. The core of Dane particles contains a circular, double-stranded DNA with an estimated molecular size of 1.6 x 10⁶ daltons and a DNA polymerase. The outer coat of Dane particle bears the antigenicity of HBsAg. The surface of the internal core expresses a distinct antigenicity called hepatitis B core antigen (HBcAg). Contained in the core particle are the unit nuclear polypeptides with an approximate molecular size of 19,000 daltons (P19). A part of P19 is exposed on the surface of core particles and expresses the antigenicity of HBcAg. Another part of P19, toward its N-terminal, bears the antigenicity of hepatitis B e antigen (HBeAg) and may appear in the circulation. Overall, therefore, there are 3 HBV-associated antigens presently identified, i.e., HBcAg, HBsAg and HBeAg. HBsAg bears the determinant a that is commonly expressed by HBV's of different strains. In addition, it bears subtype-specific antigenic determinants. From the difference in the antigenicity, 4 subtypes of HBsAg are presently recognized, i.e., adr , adw , and ayr . These subtypic antigenicities are attributed to minor differences in amino acid sequences of HBsAg coded for by HBV's of different strains. HBV is transmitted by the transfusion of blood units from HBV carriers, and also through needles and razor blades contaminated with HBV. In Japan the annual incidence of fulminant hepatitis is estimated at 4,400 cases, and that of acute hepatitis 180,000 cases. HBV infection is implicated in about 30% each of 300,000 patients with chronic hepatitis and 120,000 with liver cirrhosis. Moreover, about one half of 8,400 cases of primary hepatocellular carcinoma are suspected of having an etiology related to HBV infection. Besides such populations with overt clinical disease, there are estimated 200 million asymptomatic carriers, including 3 million in Japan. Among advanced countries, the rate of HBV carriers to the total inhabitants is the highest in Japan. People in Japan, therefore, are at highest risk of contracting HBV infection. Since the problem is a world-wide problem there exists a need for the development of efficient and safe synthetic vaccines for the prevention of HBV infection. Hepatitis B vaccines in present use are 22-nm spherical HBsAg particles purified from antigen-positive plasma and then inactivated. Limited availability of human plasma as a source of vaccine, taken together with the failure to cultivate HBV in vitro, is one of the reasons for a high price of vaccine. An additional danger is that proteins other than HBsAg, or even unidentified viruses, might co-purify in the process of preparing HBsAg from plasma. Other problems inherent in utilizing viruses to make vaccines have been mentioned above. Therefore, efforts have been made to develop synthetic vaccines. The present invention is timely in meeting with such demands, because it provides (poly)peptide vaccines that are safe and efficacious in preventing HBV infection. According to one aspect of the present invention there is provided an oligopeptide of the formulae: Asp-Pro-Arg-Val-Arg-Gly-Leu-Try-Phe-Pro-Ala-Gly-Gly-Ser-Ser-Ser-Gly-Thr-Val. According to a second aspect of the present invention there is provided an oligopeptide of the formulae Asp-Pro-Arg-Val-Arg-Gly-Leu-Tyr-Phe-Pro-Ala-Gly-Gly-Ser-Ser-Ser-Gly-Thr-Val. Preferably the polypeptide bears the receptor for polymerized human serum albumin capable of raising antibodies to inhibit the access and entry of hepatitis B virus (HBV) to hepatocytes. The present invention will now be further described with reference to the accompanying figures and examples. Fig.1 shows a schematic representation of polypeptide sequences and polypeptide processing binding sites with poly-HSA; The present invention is based on the novel findings of the applicants with regard to the attachment of HBV to hepatocytes. See the published works by the applicants and their laboratory assistants in Gastroenterology 1983, 85:268-74 and 1984; 86:910-9 the entire disclosures of which are relied on and incorporated herein. The applicants have determined that HBV gains access to hepatocytes by binding to polymerized human serum albumin (poly-HSA) which binds to the hepatocytes, in a species- and organ-specific manner, and that the amino acid sequence bearing the receptor for poly-HSA is located on HBsAg. The applicants have identified the poly-HSA receptor on a HBsAg polypeptide, P31, that can be purified from HBsAg particles derived from HBeAg-positive plasma. The major polypeptide of HBsAg, P22, did not adhere to poly-HSA, and therefore, was devoid of the receptor. Further attempts to correlate P31 with the nucleotide sequence of HBV-DNA permitted applicants to determine that the protein portion of P31 is composed of P22 made of 226 amino acid residues coded by the S region of HBV-DNA plus the 55 amino acid residues coded by the pre-S region upstream of the S region. This is shown in Figure 1. Accordingly, the poly-HSA receptor was reasonably presumed to be present on the pre-S amino acid sequence composed of 55 residues. In support of this view, the 55-amino acid pre-S polypeptide was released by splitting P31 with CNBr, and was found to bear the poly-HSA receptor. To further determine the precise amino acid sequence on P31 that is capable of binding with poly-HSA, the following was carried out: Along the nucleotide sequence on HBV-DNA's of 3 different subtypes coding for the 55-amino acid pre-S polypeptide, a sequence of 19 amino acid residues was selected that displayed a high local hydrophilicity and was expressed in common by HBV of 3 different subtypes. The peptide, synthesized chemically and named Asp-peptide, has the following sequence: Asp-Pro-Arg-Val-Aeg-Gly-Leu-Try-Phe(or-Leu)-Pro-Ala-Gly-Gly-Ser-Ser-Ser-Gly-Thr-Val. HBsAg particles without the receptor for poly-HSA, when conjugated with Asp-peptide, acquired binding activity with poly-HSA, by way of this peptide. Data in Table 1 shows the Asp-peptide reacted very well as shown by the high number of counts measured by radioactive labelling. Furthermore, Asp-peptide has now been found by the applicants to express immunogenicity, and therefore, can be used as a hepatitis B vaccine. Asp-peptide vaccine is therefore an important feature of the invention. The antibody raised against Asp-peptide in guinea pigs bound to HBsAg particles derived from HBeAg-positive plasma, but with reaction occurred with those obtained from anti-HBE-positive plasma. It has been found that antibodies raised to Asp-peptide can block the receptor on HBV and prevent it efficaciously from gaining access to hepatocytes by way of poly-HSA present on their surface. Monoclonal antibodies were raised against Asp-peptide and P31, as well as against HBsAg particles treated with SDS and 2-mercaptoethanol and split into constituent polypeptides. All monoclonals that bound to Asp-peptide could block the binding of poly-HSA with HBsAg bearing the receptor. This is shown in Table 2. These results stand in further support to the view that the Asp-peptide represents a synthetic vaccine with a remarkably high efficacy. It has been mentioned that the 9th amino acid residue of phenylalanine in the Asp-peptide may be replaced by leucine. This is attributable to a slight variation occurring in the pre-S amino acid sequences among HBV of different subtypes. On the sequence of 19 amino acid residues of Asp-peptide, the 9th residue is phenylalanine for HBV-DNA's of subtypes adr and ayw , but it is leucine for the HBV-DNA of subtype adw ; the rest of the sequence is common to HBV of the 3 different subtypes. Despite this difference, the antibodies raised against Asp-peptide with the 9th residue of phenylalanine did not show any preference for particular subtypes in binding with the pre-S polypeptide; they bound also with HBsAg particles of subtype ayw derived from HBeAg-positive plasma, as well as HBsAg particles of subtype adr and ayw . The Asp-peptide was synthesized by the solid-phase method of Merrifield et al. (Adv. Enzymol. 32 :221-296, 1969). This entire publication is relied on and incorporated herein by reference. The synthesized peptide was hydrolysed under depressurized conditions with 6 N HCl at 110°C for 24 hours, and the obtained amino acid composition was confirmed to be identical with the desired peptide. The details of the method for producing the peptide and the evaluation of its antigenicity follow. Example 1. Asp-peptides, and the polypeptide in which the 9th amino acid residue is replaced by leucine, were obtained by the following methods. The C-terminal amino acid of the intended peptide was conjugated with polystyrene after the solid-phase method of Merrifield. Then t-butoxycarbonyl amino acids were added in sequence one after another toward the N-terminal, and a 19-amino acid peptide with a sequence of Asp-Pro-Arg-Val-Arg-Gly-Leu-Try-Phe-Pro-Ala-(Gly)₂-Ser-Ser-Ser-Gly-Thr-Val (Asp-peptide) was synthesized. The peptide in which the 9th amino acid, phenylalanine, in the Asp-peptide was replaced by leucine was also synthesized. The obtained peptides were hydrolysed under a depressurized condition with 6N HCl at 110°C for 24 hours, and the amino acid composition of the intended sequence was ascertained. Example 2 Immunogenicity of the Asp-peptide of the present invention was confirmed by the following method. (1) Coupling with Chicken Egg Albumin (Ovalbumin). The Asp-peptide was coupled with ovalbumin (Sigma Chemical Co., St. Louis, MO.) that served as a carrier protein, by means of 1-ethyl-3(3-dimethylaminopropyl) carboxydimide (Sigma Chemical Co., St. Louis, MO.). 5 mg of the synthetic peptide and 1.5 mg of ovalbumin were dissolved in 5 ml of physiological saline, allowed to stand at room temperature overnight, and then dialysed against physiological saline for 2 days. (2) Immunization Female guinea pigs of the Hartley strain each received, subcutaneously, 0.1 ml of saline containing 1 mg of the synthetic peptide (conjugated with ovalbumin) emulsified in 0.2 ml of Freund's complete adjuvant. Four weeks later, the guinea pigs were boosted with the same inoculum. After an additional week, blood was obtained by cardiac puncture and the antiserum was obtained. (3) Determination of Antibody by Radioimmunoassay The activity of the obtained antisera was tested by a solid-phase sandwich-type radiommunoassay, as well as by the inhibition thereof. For the sandwich-type method, wells of a polyvinyl microtitre plate received 100 µl of buffer containing one of the following reagents at 100 µg/ml; polymerized human serum albumin, mouse monoclonal antibody against pre-S polypeptide, HBsAg particle preparation of subtype adr purified either from HBeAg-positive or anti-HBeAg-positive plasma, HBsAg particles of subtype adw derived from HBeAg-positive plasma, HBsAg particles of subtype adr isolated from HBeAg-positive plasma and then treated with pronase to deprive them of the poly-HSA receptor, P31, P22 or the synthetic peptide. The plate was incubated at room temperature for 1 hour and washed. A test sample (50 µl) was transferred to each of the wells, and the plate was incubated at 37°C for 90 min. After the plate was washed, each well received 100 µl of buffer containing radiolabelled anti HBs or monoclonal anti-pre-S, of P31. The plate was incubated at 37°C for 90 min and then washed. Wells were cut apart and the radioactivity of individual well was counted. Between each step of adding reagents, the plate was washed with saline 5 times. (4) Monoclonal Antibodies Female BALB/c mice received, intraperitoneally, one of Asp-peptide, P31 or HBsAg particles treated with SDS and 2-mercaptoethanol, each emulsified in Freund's complete adjuvant. Mice were boosted 3 weeks later with the same inoculum. After an additional 3 days, their spleen were taken out and immune spleen cells were harvested. Hybridization, cloning, and subsequent culture were performed by the method described by Oi and Herzenberg (Immunoglobulin producing hybrid cell lines. In Selected Methods in Cellular Immunology, Freeman and Co., San Francisco, pp 351-372, 1980). Culture media were tested for the antibody against the pre-S polypeptide by the following 2 different methods. In the hemagglutination assay, SRBC were coated with either HBsAg particles obtained from HBeAg-positive plasma, or the same HBsAg particles, but after treatment with pronase that deprived them of the receptor for poly-HSA. For another approach to the evaluation of the antibody specificity, wells of a microtitre plate were coated either with P31 or P22. Culture media were incubated in these wells. Subsequently, the bound immunoglobulin was detected by the rabbit anti-mouse-globulin labelled with radioiodine. Clones secreting the desired antibodies were selected and propagated in the peritoneal cavity of mice that had been made ascitic by means of Pristane. Ascites fluid was harvested after 14 days of implantation, and the 8-globulin fraction was preciptated with 1.33 M ammonium sulfate and then purified by a column of Sephadex® G-200 (Pharmacia Fine Chemicals, Piscataway, N.J.). (5) Reactivity of Monoclonal Antibodies with Various H B sAg Peptides. Eight batches of monoclonal antibody of the IgG class were tested for the inhibition of the binding of poly-HSA with HBsAg particles with the receptor in a solid-phase sandwich radioimmunoassay. See Table 2. All the monoclonals tested exhibited the inhibitory activity, thereby indicating the eligibility of Asp-peptide for use as a hepatitis B vaccine. (6) Immunogenicity of Synthetic Peptide In order to evaluate its immunogenicity, the synthetic peptide was conjugated with ovalbumin, and emulsified in Freund's complete adjuvant. The inoculum containing 1 mg of the peptide was given to each of 3 guinea pigs intracutaneously. They were boosted 4 weeks later with the same inoculum, and exanguinated after an additional week. The antisera obtained were tested for antibody activity by the sandwich-type radioimmunoassay described below. Wells of a microtitre plate were coated with one of HBsAg particles of subtype adr or adw derived from HBeAg-positive plasma, HBsAg particles of subtype adr obtained from anti-HBe-positive plasma, any one of the above HBsAg particles but after incubation with pronase, P31 or P22. The test sample was delivered to wells, and after incubation and washing, they received P31 labelled with ¹²⁵I. Thereafter, the radioactivity bound to individual well was counted. Sera from the 3 guinea pigs that had been immunized with the synthetic peptide invariably bound with the peptide as shown in Table 3. In addition, they showed binding activity with P31 (derived from HBsAg/ adr particles) and also with HBsAg particles of subtype adr and ayw isolated from HBeAg-positive plasma. These antisera, however, showed little, if any, binding activity with P22 or with HBsAg/ adr particles obtained from HBeAg-positive plasma and then deprived of P31 and P35 by a treatment with pronase. On the basis of these results, the Asp-peptide has the capacity of raising antibodies in guinea pigs that bind with HBsAg particles, derived from HBeAg-positive plasma, rich in P31 and P35. Since these antibodies can bind equally with HBsAg particles of subtypes adr and ayw , they are directed to the epitope commonly expressed by the pre-S amino acid sequence irrespective of subtypes of HBV. The peptide in which the 9th amino acid residue is replaced by leucine was tested in a similar method, and is immunogenicity was fully confirmed. Example 5 : The reactivity of the pre-S peptide was tested as follows. (1) Monoclonal Antibody (Hyb-4408) The specificity of the monoclonal antibody (Hyb-4408) directed to the pre-S region amino acid sequence of P31 is given in Table 4. This monoclonal showed a high reactivity with P31 but a low reactivity with P22, thereby attesting to its specificity to the pre-S region peptide. (2) Isolation of the Pre-S Peptide from P31 The protein component of P31 is deduced to consist of P22 and additional 55 amino acid residues on its N-terminal. Since no methionine residues between the N-terminals of P22 and that of P31 can be found, a method to split the polypeptide at methionine by means of CNBr is expected to liberate the 55-amino acid pre-S peptide from P31. The conventional conditions of the reaction in the presence of 70% formic acid and 0.1 N HCl completely inactivated the receptor for poly-HSA. Therefore, the splitting with CNBr was carried out in a solution containing SDS. After the treatment, the obtained peptides were separated by high-performance liquid chromatography. The fractions containing the presumed pre-S peptide were collected, and subjected to amino acid analysis. For the determination of amino acid composition of the obtained peptide, its content of alanine was estimated at 4 moles, as on the pre-S nucleotide sequence of HBV-DNA, and the other amino acid residues were calculated pro rata. The result obtained was essentially the same as the pre-S peptide of 55 amino acid residues that was deduced from the nucleotide sequence of the pre-S region of HBV-DNA of subtype adr . (3) Reactivity of Monoclonal Anti-Pre-S antibody (Hyb-4408) and the Pre-S Peptide Derived from P31. The pre-S peptide isolated from P31 was tested for reactivity with the monoclonal antibody (Hyb-4408) that had been raised against P31 and which had been shown to be directed to the part of P31 which was encoded by the pre-S region and thus was responsible for the receptor for poly-HSA. For this purpose, portions of buffer containing serial concentrations of pre-S peptide were incubated with a solution containing radiolabelled Hyb-4408 and incubated. An aliquot of this mixture was then transferred to wells of a microtitre plate coated with P31. The inhibition by the sample on the binding of radiolabelled Hyb-4408 with P31 was estimated using the value of similarly treated buffer as a reference as shown in Table 5. The inhibition on the binding of ¹²⁵I-Hyb-4408 increased pari passu with increasing concentrations of pre-S peptide, with linearity over a range from 3 to 100 ug/ml. These results were taken as the clear evidence for the binding of pre-S peptide with the monoclonal anti-pre-S antibody (Hyb-4408). (5) Binding of Poly-HSA with the Pre-S Peptide The pre-S peptide was tested for the reactivity with poly-HSA in a sandwich-type radioimmunoassay. The solution containing pre-S peptide was added to wells of a microtiter plate precoated with poly-HSA. The binding of the pre-S peptide to poly-HSA was then evaluated by radiolabeled monoclonal anti-pre-S antibody subsequently added to wells. As is shown in Table 6, the pre-S peptide bound with poly-HSA, thereby indicating that the receptor for poly-HSA is borne specifically by the pre-S peptide portion in P31. The vaccines of the present invention may take several different forms. They may be linked to a carrier, for example a protein carrier, e.g. tetanus toxoid, keyhole limpet hemocyanin, ovalbumin, or any other protein or polypeptide which would elicit a good T-cell response in the host. Non-protein carriers, for example lipids or liposomes, may also be used. Adjuvants may be used with the vaccines, for example aluminium hydroxide (alum), muramyl dipeptide, any acceptable oil and water combination, any substance which stimulates T helper calls such as bacterial cell components - endotoxins, cell wall components, or chemicals that stimulate T helper cells. Such carriers, adjuvants and the like are known in the art. The peptide may also be polymerized or linked to itself to produce a high molecular weight molecule or rendered immunogenic, by glutaraldehyde cross-linking for example.

Claims: An oligopeptide of the formula: Asp-Pro-Arg-Val-Arg-Gly-Leu-Tyr-Leu-Pro-Ala-Gly-Gly-Ser-Ser-Ser-Gly-Thr-Val. An oligopeptide of the formula: Asp-Pro-Arg-Val-Arg-Gly-Leu-Tyr-Phe-Pro-Ala-Gly-Gly-Ser-Ser-Ser-Gly-Thr-Val. An oligopeptide according to claim 1 or 2, bonded to protein or non-protein carrier materials. An oligopeptide according to claim 1 or 2, polymerized or linked to itself.

Inventors: MACHIDA, ATSUHIKO, NAKAMURA, TETSUO
Applicants: NAKAMURA, TETSUO
Application year: 1985
Main classification: A61K39
IPC codes: A61K39, C12P21, C07K14, C07K7, C12N15